An observational study in Prostate Cancer (Adenocarcinoma), sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by Heinrich-Heine University, Duesseldorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf — 5 open to participants now, 6 under way, none of them phase 3. Prostatic Neoplasms · Heinrich-Heine University, Duesseldorf.
Among the 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf, this one is the only one that started in 2025, is one of 4 observational ones, and was the 10th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →5 of the 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf are open now, in 1 country. Recruiting first, the newest first:
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+ · Men only
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 45–70 · Men only
Heinrich-Heine University, Duesseldorf
Ages 50–75 · Men only
Heinrich-Heine University, Duesseldorf
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 200 is close to the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 300 across the 7 interventional studies, 225 across the 4 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Heinrich-Heine University, Duesseldorf is the lead sponsor of 180 studies on the registry; 54 are open to participants now.
2 of the studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06657131Heinrich-Heine University, DuesseldorfDiagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer | 2026-11-30 |
| NCT07455097Heinrich-Heine University, DuesseldorfCOMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods. As a result, 18F-PSMA-1007 (Radelumin®) was approved in Germany and several EU countries, most recently in Germany in 01/2024, for use in primary staging of high-risk prostate cancer and re-staging in the context of biochemical recurrence (BCR). This could be seen as a milestone in the management of prostate cancer and will significantly promote the widespread use of PSMA-PET diagnostics in the coming years.
The investigators now intend to prospectively generate evidence-based data in everyday clinical practice with this so-called Real-World-Evidence (RWE) study. The planned study will enable us to analyze the diagnostic accuracy of Radelumin® in more detail under everyday conditions, whereby dedicated examinations of certain subgroups and the prospective generation of a complete, high-quality database for the future use of artificial intelligence (AI) will be made possible.
Depending on the study design and definition of the patient population, the detection rate of pelvic lymph nodes in particular using PSMA imaging is reported to be >80%. The results of the studies thus demonstrate a superior diagnostic accuracy compared to previous methods as well as a significant influence of PSMA imaging on the clinical course. Radelumin® was approved on the basis of these promising results from numerous retrospective studies and the prospective, randomized approval study.
Nevertheless, it should be noted that the results derived from such data generally deviate from the data in everyday clinical practice for various reasons. Furthermore, the retrospectively planned studies show multiple general weaknesses, whereby the prospective randomized approval studies also show a priori weaknesses. These result from a very limited observation phase and the lack of long-term data, despite good planning with a high power, a small number of patients and the targeted homogeneity of the patient population. In the context of a real-world evidence study, which focuses on routine clinical care, the above-mentioned disadvantages are compensated for by long-term observation, a considerably larger patient population and a realistic patient mix.
biologically male patients with biopsy-proven or highly suspected prostate cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Accuracy and Prognostic Value of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Cancer
1. The primary outcome will assess the diagnostic accuracy of \[18F\]PSMA-1007 PET/CT by comparing its sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) against histopathological confirmation or composite clinical follow-up as the reference standard. 2. The prognostic value will be evaluated by analyzing the association between baseline PSMA PET/CT-derived parameters (e.g., SUVmax, tumor burden, lesion distribution) and oncological outcomes, including biochemical recurrence-free survival and progression-free survival. 3. Quantitative PET parameters will be extracted using a standardized semi-automated segmentation method, and survival analysis will be conducted using Kaplan-Meier estimates and Cox proportional hazards models.
Time frame: Interim analyses will be performed annually, with a final analysis at 5 years.
Correlation of PET Parameters with Clinical and Pathological Features Description
1. The correlation between PET-derived quantitative parameters (SUVmax, metabolic tumor volume \[MTV\], total lesion PSMA expression \[TLPE\]) and clinical/pathological factors (Gleason Score, PSA level, tumor stage, lymph node involvement) will be assessed. 2. The proportion of patients whose management plan (e.g., radical prostatectomy, radiotherapy, systemic therapy) changed due to PSMA PET/CT findings compared to conventional imaging. Measured by documenting pre- and post-imaging treatment plans and analyzing changes in therapeutic strategies. 3. The relationship between baseline PSMA PET/CT findings and biochemical recurrence free survival (BRFS) will be analyzed using Kaplan-Meier survival analysis and Cox proportional hazards modeling.
Time frame: Evaluated at 1-year, 2-year, and 5-year follow-up.
Plan to share: Undecided — At a reasoble request, the study data would be provided.
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2030, 60 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 60 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heinrich-Heine University, Duesseldorf →